Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation

R. Ghalie, C. Porter, E. Radwanska, W. Fitzsimmons, Carol M Richman, H. Kaizer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We report on the use of leuprolide to prevent heavy menstrual bleeding that often occurs before platelet engraftment in premenopausal women undergoing bone marrow transplantation (BMT). Leuprolide, a synthetic analog of gonadotropin-releasing hormone (Gn-RH-a), was given to 34 patients by intravenous bolus injection, 1 mg daily, until platelet recovery. The median duration of therapy was 50 days (range 16-170). When necessary, patients self-administered the drug after discharge from the hospital. No adverse effects could be related directly to the use of leuprolide. Leuprolide effectively prevented menstruation in 25 patients (73%), failed in seven (21%), and two patients were not evaluable. The success of leuprolide therapy was related to the time of onset of treatment, as anticipated from the gradual effect of Gn-RH-a on the menstrual cycle. The failure rate was only 6% (one of 16 patients) when leuprolide was started at least 2 weeks prior to the development of thrombocytopenia, compared to a failure rate of 33% (six of 18 patients) when leuprolide was started at a later time. We conclude that leuprolide as a single agent is a safe and effective method to prevent menstrual bleeding during BMT. Additional studies are needed to determine the best timing for the onset of therapy and the relative benefit of leuprolide compared to other prophylactic approaches in patients with lengthy thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)350-353
Number of pages4
JournalAmerican Journal of Hematology
Volume42
Issue number4
StatePublished - 1993
Externally publishedYes

Fingerprint

Leuprolide
Menorrhagia
Bone Marrow Transplantation
Gonadotropin-Releasing Hormone
Thrombocytopenia
Blood Platelets
Hemorrhage
Menstruation
Therapeutics
Menstrual Cycle
Intravenous Injections

Keywords

  • BMT
  • gonadotropin-releasing hormone analogue
  • oral contraceptives
  • thrombocytopenia

ASJC Scopus subject areas

  • Hematology

Cite this

Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. / Ghalie, R.; Porter, C.; Radwanska, E.; Fitzsimmons, W.; Richman, Carol M; Kaizer, H.

In: American Journal of Hematology, Vol. 42, No. 4, 1993, p. 350-353.

Research output: Contribution to journalArticle

Ghalie, R, Porter, C, Radwanska, E, Fitzsimmons, W, Richman, CM & Kaizer, H 1993, 'Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation', American Journal of Hematology, vol. 42, no. 4, pp. 350-353.
Ghalie, R. ; Porter, C. ; Radwanska, E. ; Fitzsimmons, W. ; Richman, Carol M ; Kaizer, H. / Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. In: American Journal of Hematology. 1993 ; Vol. 42, No. 4. pp. 350-353.
@article{89dcbb2027d846b78036d83b83aa7021,
title = "Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation",
abstract = "We report on the use of leuprolide to prevent heavy menstrual bleeding that often occurs before platelet engraftment in premenopausal women undergoing bone marrow transplantation (BMT). Leuprolide, a synthetic analog of gonadotropin-releasing hormone (Gn-RH-a), was given to 34 patients by intravenous bolus injection, 1 mg daily, until platelet recovery. The median duration of therapy was 50 days (range 16-170). When necessary, patients self-administered the drug after discharge from the hospital. No adverse effects could be related directly to the use of leuprolide. Leuprolide effectively prevented menstruation in 25 patients (73{\%}), failed in seven (21{\%}), and two patients were not evaluable. The success of leuprolide therapy was related to the time of onset of treatment, as anticipated from the gradual effect of Gn-RH-a on the menstrual cycle. The failure rate was only 6{\%} (one of 16 patients) when leuprolide was started at least 2 weeks prior to the development of thrombocytopenia, compared to a failure rate of 33{\%} (six of 18 patients) when leuprolide was started at a later time. We conclude that leuprolide as a single agent is a safe and effective method to prevent menstrual bleeding during BMT. Additional studies are needed to determine the best timing for the onset of therapy and the relative benefit of leuprolide compared to other prophylactic approaches in patients with lengthy thrombocytopenia.",
keywords = "BMT, gonadotropin-releasing hormone analogue, oral contraceptives, thrombocytopenia",
author = "R. Ghalie and C. Porter and E. Radwanska and W. Fitzsimmons and Richman, {Carol M} and H. Kaizer",
year = "1993",
language = "English (US)",
volume = "42",
pages = "350--353",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation

AU - Ghalie, R.

AU - Porter, C.

AU - Radwanska, E.

AU - Fitzsimmons, W.

AU - Richman, Carol M

AU - Kaizer, H.

PY - 1993

Y1 - 1993

N2 - We report on the use of leuprolide to prevent heavy menstrual bleeding that often occurs before platelet engraftment in premenopausal women undergoing bone marrow transplantation (BMT). Leuprolide, a synthetic analog of gonadotropin-releasing hormone (Gn-RH-a), was given to 34 patients by intravenous bolus injection, 1 mg daily, until platelet recovery. The median duration of therapy was 50 days (range 16-170). When necessary, patients self-administered the drug after discharge from the hospital. No adverse effects could be related directly to the use of leuprolide. Leuprolide effectively prevented menstruation in 25 patients (73%), failed in seven (21%), and two patients were not evaluable. The success of leuprolide therapy was related to the time of onset of treatment, as anticipated from the gradual effect of Gn-RH-a on the menstrual cycle. The failure rate was only 6% (one of 16 patients) when leuprolide was started at least 2 weeks prior to the development of thrombocytopenia, compared to a failure rate of 33% (six of 18 patients) when leuprolide was started at a later time. We conclude that leuprolide as a single agent is a safe and effective method to prevent menstrual bleeding during BMT. Additional studies are needed to determine the best timing for the onset of therapy and the relative benefit of leuprolide compared to other prophylactic approaches in patients with lengthy thrombocytopenia.

AB - We report on the use of leuprolide to prevent heavy menstrual bleeding that often occurs before platelet engraftment in premenopausal women undergoing bone marrow transplantation (BMT). Leuprolide, a synthetic analog of gonadotropin-releasing hormone (Gn-RH-a), was given to 34 patients by intravenous bolus injection, 1 mg daily, until platelet recovery. The median duration of therapy was 50 days (range 16-170). When necessary, patients self-administered the drug after discharge from the hospital. No adverse effects could be related directly to the use of leuprolide. Leuprolide effectively prevented menstruation in 25 patients (73%), failed in seven (21%), and two patients were not evaluable. The success of leuprolide therapy was related to the time of onset of treatment, as anticipated from the gradual effect of Gn-RH-a on the menstrual cycle. The failure rate was only 6% (one of 16 patients) when leuprolide was started at least 2 weeks prior to the development of thrombocytopenia, compared to a failure rate of 33% (six of 18 patients) when leuprolide was started at a later time. We conclude that leuprolide as a single agent is a safe and effective method to prevent menstrual bleeding during BMT. Additional studies are needed to determine the best timing for the onset of therapy and the relative benefit of leuprolide compared to other prophylactic approaches in patients with lengthy thrombocytopenia.

KW - BMT

KW - gonadotropin-releasing hormone analogue

KW - oral contraceptives

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0027536861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027536861&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 350

EP - 353

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -